![[up]](/style/images/multi_up.png)
Up a levelGroup by: Item Type | Date
Jump to: Journal article
Number of items: 3.
Journal article
Personeni, Nicola; Giordano, Laura; Abbadessa, Giovanni; Porta, Camillo; Borbath, Ivan; Daniele, Bruno; Laethem, Jean-Luc van; Vlierberghe, Hans van; Trojan, Jörg; Toni, Enrico N. de; Gasbarrini, Antonio; Lencioni, Monica; Lamar, Maria E.; Wang, Yunxia; Shuster, Dale; Schwartz, Brian; Santoro, Armando und Rimassa, Lorenza
(2017):
Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma.
In: Oncotarget, Vol. 8, No. 9: pp. 14408-14415
Rimassa, Lorenza; Abbadessa, Giovanni; Personeni, Nicola; Porta, Camillo; Borbath, Ivan; Daniele, Bruno; Laethem, Jean-Luc van; Vlieberghe, Hans van; Trojan, Jorg; de Toni, Enrico; Peck-Radosavljevic, Markus; Finn, Richard S.; Raoul, Jean-Luc; He, Aiwu Ruth; Lamar, Maria; Wang, Yunxia; Roemeling, Reinhard W. von; Schwartz, Brian E.; Bruix, Jordi und Santoro, Armando
(2016):
Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).
In: Journal of Clinical Oncology, Vol. 34, No. 4
Rimassa, Lorenza; Abbadessa, Giovanni; Personeni, Nicola; Porta, Camillo; Borbath, Ivan; Daniele, Bruno; Salvagni, Stefania; Laethem, Jean-Luc van; Vlierberghe, Hans van; Trojan, Jörg; De Toni, Enrico N.; Weiss, Alan; Miles, Steven; Gasbarrini, Antonio; Lencioni, Monica; Lamar, Maria E.; Wang, Yunxia; Shuster, Dale; Schwartz, Brian E. und Santoro, Armando
(2016):
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.
In: Oncotarget, Vol. 7, No. 45: pp. 72622-72633